Data from a large European screening program indicate that people who actively took part in colorectal cancer screening had a ...

Colorectal cancer is no longer a disease that mostly strikes people in their 60s and 70s. It has quietly become the leading cause of cancer deaths in Americans under 50, and doctors still cannot fully ...

Forbes contributors publish independent expert analyses and insights. Physician who writes about the rising rates of cancer in young adults. This voice experience is generated by AI. Learn more. This ...

She was doing everything right. She exercised, ate well, and stayed active with her husband and two teenage daughters. She ...

Forbes contributors publish independent expert analyses and insights. Physician who writes about the rising rates of cancer in young adults. Colon cancer is a leading cause of cancer-related deaths.

“Although screening is offered free of charge and the test is simple to carry out, around a third of people do not submit a ...

Colon cancer remains a significant health concern, particularly within the Black community, where the disease disproportionately affects individuals. A recent study led by researcher Adjoa ...

People who participated in colorectal cancer screening had a 43% lower risk of dying from the disease, according to long-term data from more than 376,000 people in Sweden. The findings suggest that ...

Add Yahoo as a preferred source to see more of our stories on Google. Kentucky has long carried one of the highest burdens of colorectal cancer in the nation. For too many families, it is a diagnosis ...

With rates of colorectal cancer (CRC) surging among younger populations, Guardant Health is turning to a famous face beloved by Gen X and millennials to raise awareness of its screening test. The ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) will be covered in Carelon Healthcare Services ...

The experimental DENEB test found early cancers and precancerous polyps in an international trial published this month.